Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / C••

NewVale Capital Invests in CAI, a Leading Provider of Commissioning, Qualification and Validation Services Read

Majority recapitalizationannouncedannounced Jul 1, 2026Fact
What happened
Target
C••
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
healthcare / life sciences
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
2 named
Buy side
  • N•••••• C•••••• L••Sponsorconfirmed
    “NewVale Capital (“NewVale”), a sector-specialist pharma services growth equity firm, today announced its investment in CAI as part of the company’s recapitalization led by JLL Partners.”
Side not stated
  • C••Targetconfirmed
    “NewVale Capital (“NewVale”), a sector-specialist pharma services growth equity firm, today announced its investment in CAI as part of the company’s recapitalization led by JLL Partners.”
Evidence
“NewVale Capital (“NewVale”), a sector-specialist pharma services growth equity firm, today announced its investment in CAI as part of the company’s recapitalization led by JLL Partners.”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 18, 2026
NewVale Capital Invests in CAI, a Leading Provider of Commissioning, Qualification and Val | Private Equity Intelligence | DFX